Zafgen (ZFGN) Tops Q3 EPS by 22c

Zafgen (NASDAQ: ZFGN) reported Q3 EPS of ($0.65), $0.22 better than the analyst estimate of ($0.87).

As a result of increased clarity related to the timing of certain pre-clinical and clinical expenses, the Company now expects to end 2014 with greater than $100 million in cash and cash equivalents, as compared to the previous estimate of greater than $95 million.

For earnings history and earnings-related data on Zafgen (ZFGN) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Eikon Therapeutics, Inc. (EIKN) Misses Q2 EPS by 163c
• Hitachi Ltd. (HIT) Misses Q2 EPS by 7c